He is an Honorary Consultant Haematologist at The Royal Marsden NHS Foundation Trust, specialised in the management of multiple myeloma and related precursor conditions, smouldering myeloma and MGUS.

Professor Kaiser’s key interest is the genetic and immune environment characterisation of multiple myeloma, a cancer of bone marrow plasma cells, with the aim of designing gentler, tailored therapies for patients. A particular focus of his work is high-risk myeloma. His team conducted the OPTIMUM trial, one of the first trials globally to offer innovative diagnostics and tailored therapy for patients with high-risk myeloma, which translated basic research from his team’s work into clinical application.

Beyond molecular studies, and in collaboration with Dr Christina Messiou and Dr Robyn Shea at The Royal Marsden Hospital, Professor Kaiser works on development of next-generation clinical diagnostics for myeloma and myeloma precursor conditions, including advanced functional, diffusion-weighted MRI imaging technology and mass-spectrometry blood based activity monitoring, respectively.

Professor Kaiser has an interest in regulatory policy. He is member of the European Medicine Agency / EORTC Cancer Medicines Forum and member of the European Haematology Association’s European Affairs Committee and Clinical Research Committees. He is vice chair of the UK Myeloma Research Alliance (UKMRA), and executive board member of the UK Myeloma Society, joining research, policy and advocacy work, to bring the results of UK research closer to patients.

Professor Kaiser was the first Jacquelin Forbes-Nixon Research Fellow, supported by the David Forbes-Nixon Charitable Foundation in collaboration with Myeloma UK.